Trial Profile

A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVX 01 (Primary) ; EVX 01 (Primary) ; Nivolumab; Pembrolizumab
Indications Bladder cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms NeoPepVac

Most Recent Events

15 Jan 2025 According to a Evaxion media release, the trial remains on track for completion and data readout is expected in the second half of 2025.
14 Aug 2024 According to a Evaxion media release, company is on track for Phase 2 one-year clinical data readout at the ESMO Congress 2024 in September (Q3 2024).
17 Jun 2024 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com